Tag: Complement Pathway

  • FDA Approves YARTEMLEA: A Breakthrough in Complement Pathway Inhibition

    FDA Approves YARTEMLEA: A Breakthrough in Complement Pathway Inhibition

    The final days of 2025 witnessed a significant milestone in transplantation medicine, as the Food and Drug Administration granted approval to YARTEMLEA (narsoplimab-wuug) on December 24th—the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). This approval represents more than a mere regulatory achievement; it marks the culmination of decades of…